In this episode, Robert sits down with his long-time research partner and neuroscientist Martin Junggebauer to cover two of the most clinically significant topics in light medicine today, antimicrobial photodynamic therapy for drug-resistant infectious disease, and transcranial photobiomodulation for neurodegeneration. Martin brings 13 years of field research to the conversation, including co-authoring the first published human study on systemic photodynamic therapy for malaria, and breaking down why the same mechanism applies to Lyme disease, hepatitis, chronic viral load, and beyond. The second half of the episode goes deep into brain PBM: the exact mechanisms driving neurodegeneration, the research on Alzheimer's, Parkinson's, depression, and autism, and why the new laser helmet technology changes what's clinically possible. In this episode, we cover: The Malaria Study: How a 13-year research journey led to the first published human trial on systemic antimicrobial photodynamic therapy, and what 120 patients revealed about parasite clearance rates vs. standard drug protocols. The Riboflavin Protocol: Why riboflavin binds to pathogen DNA with 99.9% selectivity, how UV and blue laser activation at precise wavelengths destroys the pathogen without harming healthy cells, and why drug resistance cannot develop against this mechanism. Beyond Malaria: How the same photodynamic principle applies systemically to bacteria, viruses, fungi, and chronic infections including Lyme disease and hepatitis. The 3 Root Causes of Neurodegeneration: Why chronic neuroinflammation, mitochondrial dysfunction, and impaired cerebral blood flow are the core hallmarks of almost every brain disorder, and how infrared light addresses all three simultaneously. The Glymphatic System: How brain PBM enhances the brain's own waste removal system through four distinct mechanisms, including increasing cerebrospinal fluid flow and upregulating aquaporin-4 water channel proteins. The Research: A review of 36 studies on Alzheimer's and dementia, every one reporting beneficial results, plus Parkinson's patients who continued improving for 5 years of home-based treatment. Laser vs. LED for Brain Therapy: Why power density is the critical variable, why most existing studies were conducted with underpowered LED devices, and what the new laser helmet makes possible for the first time. Children and Autism: Why brain PBM is safe for children, how to adjust dosage by body weight, and what studies on kids as young as five years old revealed about social communication and behavior improvements. About the Guest: Martin Junggebauer is a neuroscientist, researcher, and co-founder of the Insights program, a comprehensive integrative health project combining photobiomodulation, infusion therapies, mindset, and lifestyle for neuroregenerative outcomes. He co-authored the first human study on antimicrobial photodynamic therapy and has spent 13 years advancing the science of light medicine alongside Weber Medical. Connect with Martin: Substack: Light and Equanimity - https://lightandequanimity.substack.com/ LinkedIn: https://www.linkedin.com/in/martin-junggebauer-3892b566/ Website: martinjunggebauer.com Email: junggebauer@webermedical.com Connect with Weber Medical: Website: https://www.webermedical.com LinkedIn: / webermedical Disclaimer: The content of this podcast is for educational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment.
